Sino Biopharmaceutical Ltd. / LaNova Medicines Ltd.
2025 · Acquisition/Merger · $951M · Complete
Announcement Sentiment
70
Positive
Sino Biopharm agreed to acquire the ~95% of LaNova Medicines it didn't already own for up to $951M (net cash outlay ~$500M). Adds eight clinical-stage oncology assets including LM-299 (Merck-licensed PD-1/VEGF bispecific) and three ADCs, plus ~20 preclinical programs.